# NCT04897321 (NCT04897321)

> B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04897321
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: St. Jude Children's Research Hospital
- Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
- Interventions: Fludarabine; Cyclophosphamide; MESNA; B7-H3 CAR T cells
- Enrollment: 48
- Primary outcome: Safety of B7-H3-CAR T cells

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 14
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct04897321

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04897321", "email": "<work email>"}; the inbox owner confirms by the emailed link.